PTC Therapeutics, Inc. filed an 8-K on October 30, 2026, disclosing that its Compensation Committee approved inducement equity awards on October 28, 2026, consisting of stock options and restricted stock units granted to 13 new employees under the Nasdaq inducement grant exception.

Key Highlights

  • Awards approved: Options to purchase an aggregate of 9,620 shares of common stock and 11,535 RSUs were granted to 13 new employees on October 28, 2026.
  • Exercise price: All stock options carry an exercise price of $63.02 per share, the closing price of PTC's common stock on October 28, 2026.
  • Option term and vesting: Each stock option has a 10-year term and vests over four years, with 25% vesting on the first anniversary of the employee's new hire date and 6.25% vesting at the end of each subsequent three-month period thereafter.
  • RSU vesting: Each RSU award vests over four years, with 25% vesting on each annual anniversary of the applicable employee's new hire date until fully vested.
  • Regulatory basis: The awards were made pursuant to Nasdaq Listing Rule 5635(c)(4) as an inducement material to each employee's acceptance of employment with the company.
  • Approving body: PTC's Compensation Committee approved the inducement grants on October 28, 2026.

PTC Therapeutics Issues October 28, 2026 Inducement Equity Grants to 13 New Employees

According to the filing, PTC Therapeutics, Inc. (NASDAQ:PTCT) announced on October 30, 2026, that its Compensation Committee approved non-statutory stock options covering an aggregate of 9,620 shares of common stock and 11,535 restricted stock units to 13 new employees. The company disclosed that the awards were made pursuant to the Nasdaq inducement grant exception and serve as a component of the new hires' employment compensation.

The company reported that all stock option awards have an exercise price of $63.02 per share, which the filing identifies as the closing price of PTC's common stock on October 28, 2026, the grant date. Each option carries a 10-year term. Vesting is structured so that 25% of the original shares vest on the first anniversary of each employee's new hire date, followed by 6.25% vesting at the end of each subsequent three-month period until fully vested, subject to continued service through applicable vesting dates.

For the RSU awards, the filing states that each award vests over four years, with 25% of the original shares vesting on each annual anniversary of the applicable employee's new hire date until fully vested, also subject to the employee's continued service. The company noted the grants were made in accordance with Nasdaq Listing Rule 5635(c)(4), which provides an exception allowing inducement grants without shareholder approval when they are material to a new employee's acceptance of employment.

What Was Disclosed

PTC Therapeutics disclosed Compensation Committee-approved inducement equity grants dated October 28, 2026, covering 9,620 stock options at $63.02 per share and 11,535 RSUs, awarded to 13 new employees under Nasdaq Listing Rule 5635(c)(4).